SM
RIGL icon

Sabby Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Sabby Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-32
Closed -$116K – 325
2016
Q3 		$116K Sell
32
-136
-81% -$3.9K ﹤0.01% 287
2016
Q2 		$375K Buy
+168
New +$4.18K 0.02% 224

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sabby Management's RIGL Position: Q1 2017 in Review

Sabby Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2017, closing a stake of 1,235 shares — an estimated $29K sold.

Sabby Management first reported a position in RIGL in Q3 2013 and held it in 5 quarters. The position peaked at $2.17M in Q4 2013. 99 funds tracked by Wall St. Rank hold RIGL as of Q1 2017.

  • Sabby Management reported no remaining Rigel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 1,235 Rigel Pharmaceuticals shares in Q1 2017, an estimated $29K.
  • Sabby Management first reported a position in Rigel Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • Sabby Management's Rigel Pharmaceuticals position peaked at $2.17M in Q4 2013.
  • 99 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.